» Articles » PMID: 16670313

Targeting Melanoma Cells with Human High Molecular Weight-melanoma Associated Antigen-specific Antibodies Elicited by a Peptide Mimotope: Functional Effects

Overview
Journal J Immunol
Date 2006 May 4
PMID 16670313
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Human high molecular weight-melanoma associated Ag (HMW-MAA) mimics have been shown to elicit HMW-MAA-specific humoral immune responses that appear to be clinically beneficial. This finding has stimulated interest in characterizing the mechanism(s) underlying the ability of the elicited Abs to exert an anti-tumor effect. To address this question, in the present study, we have generated HMW-MAA-specific Abs by sequentially immunizing rabbits with the peptide P763.74, which mimics the HMW-MAA determinant recognized by mAb 763.74, and with HMW-MAA(+) melanoma cells. HMW-MAA-specific Abs isolated from immunized rabbits mediated cell-dependent cytotoxicity but did not mediate complement-dependent cytotoxicity of HMW-MAA(+) melanoma cells. These Abs also effectively inhibited spreading, migration and Matrigel invasion of HMW-MAA(+) melanoma cells. Besides contributing to our understanding of the role of HMW-MAA in the biology of melanoma cells, these results suggest that both immunological and nonimmunological mechanisms underlie the beneficial clinical effects associated with the induction of HMW-MAA-specific Abs in melanoma patients immunized with a HMW-MAA mimic.

Citing Articles

Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma.

Chen X, Habib S, Alexandru M, Chauhan J, Evan T, Troka J Cancers (Basel). 2024; 16(19).

PMID: 39409881 PMC: 11476251. DOI: 10.3390/cancers16193260.


Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.

Kurokawa T, Imai K Proc Jpn Acad Ser B Phys Biol Sci. 2024; 100(5):293-308.

PMID: 38735753 PMC: 11260911. DOI: 10.2183/pjab.100.019.


Filamentous Bacteriophage-A Powerful Carrier for Glioma Therapy.

Wang Y, Sheng J, Chai J, Zhu C, Li X, Yang W Front Immunol. 2021; 12:729336.

PMID: 34566987 PMC: 8462735. DOI: 10.3389/fimmu.2021.729336.


The development of inovirus-associated vector vaccines using phage-display technologies.

Stern Z, Stylianou D, Kostrikis L Expert Rev Vaccines. 2019; 18(9):913-920.

PMID: 31373843 PMC: 7103683. DOI: 10.1080/14760584.2019.1651649.


Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.

Ilieva K, Cheung A, Mele S, Chiaruttini G, Crescioli S, Griffin M Front Immunol. 2018; 8:1911.

PMID: 29375561 PMC: 5767725. DOI: 10.3389/fimmu.2017.01911.